Table 2.

Difference between PTLD and lymphomas developing in immunocompetent individuals

	Incidence	EBV association	Site of disease involvement	Type of lymphomas	Treatment modality
Lymphomas in immunocompetent	.2–4% of general population	Rare	Nodal > extranodal	NHL (B > T) HL	Chemotherapy Rituximab HSCT
PTLDs	20% of transplant recipients	10–75% of all cases	Extranodal > nodal	Early lesions Polymorphic Monomorphic Hodgkin’s like	Reducing immunosuppression Rituximab Chemotherapy Adoptive therapy Immunomodulatory agents

NHL non Hodgkin lymphoma, HL Hodgkin’s lymphoma, HSCT hematopoietic stem cell transplant